Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1956 2
1957 1
1959 2
1962 1
1964 1
1965 2
1967 1
1968 1
1969 1
1970 2
1973 3
1974 8
1975 6
1976 1
1977 9
1978 4
1979 4
1980 5
1981 6
1982 4
1983 3
1984 3
1985 2
1986 4
1987 2
1988 4
1989 7
1990 5
1991 9
1992 2
1993 3
1994 7
1995 5
1996 4
1997 3
1998 2
2002 2
2003 3
2004 4
2005 4
2006 1
2007 6
2008 3
2009 5
2010 4
2011 2
2012 1
2013 4
2014 1
2015 1
2017 1
2018 1
2023 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

170 results

Results by year

Filters applied: . Clear all
Page 1
Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).
Ho D, Huang J, Chapman JW, Leitzel K, Ali SM, Shepherd L, Parulekar WR, Ellis CE, Crescnzo RJ, Zhu L, Virk S, Nomikos D, Aparicio S, Gelmon KA, Carney WP, Lipton A. Ho D, et al. Among authors: carney wp. Breast Cancer Res Treat. 2017 Aug;164(3):571-580. doi: 10.1007/s10549-017-4273-x. Epub 2017 May 8. Breast Cancer Res Treat. 2017. PMID: 28484925 Clinical Trial.
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
Moreno-Aspitia A, Hillman DW, Dyar SH, Tenner KS, Gralow J, Kaufman PA, Davidson NE, Lafky JM, Reinholz MM, Lingle WL, Kutteh LA, Carney WP, Dueck AC, Perez EA. Moreno-Aspitia A, et al. Among authors: carney wp. Cancer. 2013 Aug 1;119(15):2675-82. doi: 10.1002/cncr.28130. Epub 2013 Jun 6. Cancer. 2013. PMID: 23744760 Free PMC article. Clinical Trial.
Microfluidics and circulating tumor cells.
Dong Y, Skelley AM, Merdek KD, Sprott KM, Jiang C, Pierceall WE, Lin J, Stocum M, Carney WP, Smirnov DA. Dong Y, et al. Among authors: carney wp. J Mol Diagn. 2013 Mar;15(2):149-57. doi: 10.1016/j.jmoldx.2012.09.004. Epub 2012 Dec 22. J Mol Diagn. 2013. PMID: 23266318 Free article. Review.
Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.
Lipton A, Leitzel K, Ali SM, Carney W, Platek G, Steplewski K, Westlund R, Gagnon R, Martin AM, Maltzman J. Lipton A, et al. Among authors: carney w. Cancer. 2011 Nov 1;117(21):5013-20. doi: 10.1002/cncr.26101. Epub 2011 Mar 31. Cancer. 2011. PMID: 21456017 Free article.
170 results